Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00431067 · ClinicalTrials.gov registry record · Phase 2
Phase II Trial of BIBW 2992 in Patients With HER2-positive Metastatic Breast Cancer After Failure of Trastuzumab Therapy
A Phase 2 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
NCT00431067 is a Phase 2 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 41 participants.
The verdict
NCT00431067, a Phase 2 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
Study Summary
The primary objective of this trial is to explore the efficacy of BIBW 2992 in HER2 positive metastatic breast cancer patients after failure of trastuzumab containing regimens.
Interventions
- DRUG BIBW 2992
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2006-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00431067
The ClinicalTrials.gov registry entry for NCT00431067 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BIBW 2992 is the first listed.
NCT00431067 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00431067 about?
NCT00431067 is a clinical study titled "Phase II Trial of BIBW 2992 in Patients With HER2-positive Metastatic Breast Cancer After Failure of Trastuzumab Therapy". The primary objective of this trial is to explore the efficacy of BIBW 2992 in HER2 positive metastatic breast cancer patients after failure of trastuzumab containing regimens.
What is the current status of trial NCT00431067?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2006-09.
What interventions are being tested in trial NCT00431067?
The interventions under investigation include: BIBW 2992 (DRUG).
Who is sponsoring clinical trial NCT00431067?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.